Loading…
Loading…
SYNB (Putnam BioRevolution ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.
Is SYNB's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
SAN MATEO, Calif.--(BUSINESS WIRE)--Franklin Templeton today announced it will liquidate and dissolve Putnam BioRevolution™ ETF (SYNB). The liquidation is anticipated to occur on or about November 21, 2025, although the Fund may make dispositions of portfolio holdings prior to the liquidation date. Effective as of the close of business on October 24, 2025, the Fund will no longer accept orders for the purchase of creation units, and effective as of the close of business on November 13, 2025, th.
Putnam Investments announced that on Friday, September 30, it will launch two new transparent, actively managed, equity exchange traded funds: the Putnam BDC Income ETF (NYSE Arca: PBDC), concentrating on business development companies (BDCs), and the Putnam BioRevolution ETF (NYSE Arca: SYNB), centered on companies operating at the intersection of technology and biology in the “biology revolution.